Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer

Pankaj Wanjarkhedkar1, Padmaj Kulkarni1, Sachin Hingmire1, Dhananjay Kelkar1, Kamlesh Bokil2

1 Department of Oncology - VLM Cancer Center; Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India
2 Dwidal Nursing Home, Pune, Maharashtra, India

Address for correspondence Pankaj Wanjarkhedkar, MD Ayurveda, Department of Oncology - VLM Cancer Center; Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India (e-mail: drwpankaj@gmail.com).

Abstract

Despite optimal surgery and first-line platinum-based doublet chemotherapy, approximately 70 to 80% of patients with epithelial ovarian cancers relapse. Two cases of recurrent ovarian cancer (ROC) were treated with non–platinum-based Ayurveda maintenance therapy (AMT) consisting of drugs having a herbal and herbomineral origin. This regimen was followed over a period of 3 years and progression-free survival (PFS) was noted along with platinum-free interval (PFI). Two patients were diagnosed with BRCA1 mutated recurrent high-grade serous ovarian carcinoma and treated with the per-oral AMT regimen labeled as ZINCA-30 in our hospital after completion of standard of care treatment and followed up until progression. The ZINCA-30 regimen comprising Jasada (traditional Zinc preparation), Indukanth kwatham and Curcuma amada powder in combination was prescribed based on Rasayana chikitsa postulated in Ayurveda. The patients were followed up every 3 months. The progression-free survival observed in these patients was 28 months and 36.3 months, respectively. These two pilot cases suggested an increased platinum-free interval (PFI), improved progression-free survival (PFS) in recurrent ovarian cancer (ROC), with the AMT labeled as ZINCA-30 after chemotherapy.

Keywords

► recurrent ovarian cancer
► progression-free survival
► platinum-free interval
► ayurveda maintenance treatment
► ZINCA-30

Introduction

Despite optimal surgery and first-line platinum-based doublet chemotherapy, approximately 70 to 80% of patients with epithelial ovarian cancers show a relapse.1 The most important features that influence the treatment choice in recurrent ovarian cancer (ROC) with respect to systemic therapy are tumor histology, BRCA mutation status, platinum-free interval (PFI), and previous treatment with an anti-VEGF monoclonal antibody. The presence of germline or somatic BRCA mutations allows platinum-responsive patients to optimize the chemotherapy efficacy and prolong progression-free survival (PFS) using a PARP inhibitor given as maintenance therapy until progression.1

Response to platinum re-treatment in recurrent epithelial ovarian cancer is related to PFI. The most preferred and accepted chemotherapy in the treatment of platinum-sensitive (PFI > 6 months) recurrence is platinum-based combination regimens. It is considered that extending the PFI with non-platinum agents may enhance the response and the outcome of subsequent re-challenge with platinum.2

Therefore, the exploration for therapies with minimal toxicities to increase the PFS was initiated. Time to relapse
is an important prognostic factor in ovarian cancer as subsequent chemoresponse is based on this time interval.3

In the doctrines of Ayurveda, the clinical stages and treatments for benign and malignant tumors have been discussed in detail.4

Rasayana chikitsa is one of the therapeutic segments of Ayurveda, which helps to improve immunity, consists of compounds having immune-stimulant, immune-modulator effects and hence they restore health.5 A regimen with drugs having anti-cancer properties and predominant Rasayana herbs and minerals has been described here for the management of ROC.

Methodology

We report the detailed course as elaborated in Table 1 and the follow-up of Ayurveda maintenance treatment (AMT) labeled as ZINCA-30 in two cases of recurrent high-grade serous ovarian cancer in our institution. Two BRCA mutated patients (refer to Table 1 for details) of ROC were offered AMT ZINCA-30. These patients after completing the standard chemotherapy were not willing for any conventional maintenance therapy and had opted for ZINCA-30.

The per-oral ZINCA-30 regimen prescribed for both the patients has standardized Jadad Bhasma (JB), Indukanth Kwatham (IK) tablets and powdered Amra-Haridra (AH) (Curcuma amada); daily dosage to be continued until the next recurrence. IK tablets (the detailed composition is mentioned in Supplementary Table S1) (3,600 mg/day) were prescribed 30 minutes before food, while the JB (10 mg/kg/day) and AH (1,200 mg/day) combination was advised to be taken after consuming food.

The treatment was started after the last chemotherapy cycle in both patients. These patients were followed up 3 monthly with clinical as well as laboratory evaluation including biochemistry, CA 125, and sonological evaluation of the abdomen and pelvis.

Patient 1 (PSK) was on regular follow-up until November 2020 when she presented with mild pain in the abdomen. Her clinical examination was unremarkable and CA-125 level was normal. A PET CT evaluation on 02/11/2020 showed nodal recurrence along the right iliac vein and a mesenteric node. Thus, she had a PFS of 28 months after three earlier recurrences as mentioned in Table 1.

She was treated with six cycles of paclitaxel and carboplatin from 06/11/2020 to 01/03/2021 and is now in complete regression (CR) as reported in PET CT dated 03/04/2021.

Patient 2 (BSK) has had a PFS of 36.3 months and has shown no signs of relapse at the time of submitting the manuscript. The CA-125 level was within normal range throughout the period of observation until the last follow-up in both the patients (Supplementary Table S2). The mean ± standard deviation (SD) value of CA-125 in U/mL was 5.15 ± 1.12 in patient 1-PSK and 7.72 ± 1.61 in patient 2-BSK, over the total duration of follow-up.

All hematological and biochemical parameters including liver function tests and renal function tests were observed to be within the normal limit (Supplementary Table S3.

Discussion

Epithelial ovarian cancer (EOC) is the most fatal among recurring gynecological malignancies and around 75% of females with EOC are diagnosed at FIGO stage III or IV.6

The median PFI of 11.9 months (interquartile range [IQR]: 3.6–21.9) among 28 recurred patients with the median number of treatment lines 4 (IQR: 3–6) and median of 2 (IQR: 2–3) platinum lines was observed in a retrospective study between 2004 and 2014 with at least 3 years follow-up among 40 BRCA mutation carriers (26 BRCA1 and 14 BRCA2) with a mean age of 54 years, all underwent cytoreduction surgery and received platinum chemotherapy.7

GOG-0218 (PFS 14.1 vs. 10.3, p < 0.001) and ICON7 (PFS 19.8 vs. 17.4, p < 0.001) trials suggested that the use of bevacizumab maintenance after standard chemotherapy prolongs median PFS in ROC patients.8

In the AGO-OVAR-16 trial, pazopanib maintenance therapy for 24 months after the completion of first-line platinum-based therapy improved PFS by 5.6 months compared with placebo.9 SOLO2 investigated olaparib maintenance after ≥ 2 lines of chemotherapy for ovarian cancer patients with germline BRCA mutations. The study concluded that olaparib significantly improved PFS as compared with placebo (19.1 months vs. 5.5 months, p < 0.0001).10

The maintenance treatment options are being explored in the ROC setting including targeted therapy with vascular endothelial growth factor (VEGF) inhibitors such as bevacizumab and tyrosine kinase inhibitors (TKI) such as pazopanib and nintedanib.11

Fatigue, hematological, and GI toxicities are the most commonly observed adverse events with PARPi therapy.12 GI tract symptoms such as nausea, vomiting, anemia, neutropenia, fatigue, and abdominal pain are reported as primary adverse effects. Rare but serious adverse events of developing acute myeloid leukemia (AML) have been reported with phase III study of olaparib.13

In the phase 3 AGO-OVAR 16 study, grade 3 or 4 AEs of hypertension (30.8%), neutropenia (9.9%), liver-related toxicity (9.4%), diarrhea (8.2%), fatigue (2.7%), thrombocytopenia (2.5%), and palmar-plantar erythrodysesthesia (1.9%) were significantly higher in the pazopanib arm than with placebo, and the treatment-related discontinuation rate was also higher with pazopanib (33.3% vs. 5.6%).14

It has been observed in two phase III clinical trials in newly diagnosed advanced-stage ovarian cancer GOG 218 and GOG 262, around 18% of EOC were associated with BRCA1 and BRCA2 mutations and differed in tumor biology and treatment response.15

The platinum-free interval is the most important predictive factor for a response to subsequent lines of chemotherap-y. It is also the most important prognostic factor for PFS and overall survival (OS) in patients with ROC. A non-platinum regimen is generally preferred as the most appropriate

---

**Table 1**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Duration of Follow-Up</th>
<th>Chemotherapy</th>
<th>Maintenance Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSK</td>
<td>54</td>
<td>28 months</td>
<td>Paclitaxel</td>
<td>ZINCA-30</td>
</tr>
<tr>
<td>BSK</td>
<td>54</td>
<td>36.3 months</td>
<td>Paclitaxel</td>
<td>ZINCA-30</td>
</tr>
</tbody>
</table>

**Supplementary Table S1**

<table>
<thead>
<tr>
<th>Composition</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>JB</td>
<td>3,600 mg/day</td>
</tr>
<tr>
<td>IK</td>
<td>30 minutes before food</td>
</tr>
<tr>
<td>AH</td>
<td>1,200 mg/day</td>
</tr>
</tbody>
</table>

**Supplementary Table S2**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA-125</td>
<td>5.15 ± 1.12 U/mL</td>
</tr>
<tr>
<td></td>
<td>7.72 ± 1.61 U/mL</td>
</tr>
</tbody>
</table>

**Supplementary Table S3**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver function tests</td>
<td>Within normal limit</td>
</tr>
<tr>
<td>Renal function tests</td>
<td>Within normal limit</td>
</tr>
</tbody>
</table>
approach when the disease recurs early after the chemotherapy, and platinum-based chemotherapy is usually recommended if the platinum-free interval exceeds 12 months.\textsuperscript{16}

The goals of therapy in ROC should be palliation of cancer-related symptoms, maintenance of the quality of life, and extension of life. Hence, there is a significant impetus for research for focusing on newer maintenance treatments for ROC.\textsuperscript{17}

Therefore, the option of ATM was explored with the effective role of Rasayana properties of the herbs and minerals in the ZINCA-30 regimen.

Rasayana drugs in Ayurveda are herbal/herbomineral preparations or individual herbs used to rejuvenate or attain the complete potential of an individual to prevent diseases and degenerative changes that lead to the disease. The probable mechanism may be immune-stimulation, quenching free radicals, enhancing cellular detoxification mechanisms, repairing damaged non-proliferating cells, inducing cell proliferation, and self-renewal of damaged proliferating tissues, and replenishing those by replacing damaged or mutated cells with fresh cells.\textsuperscript{18}

A combination labeled as ZINCA-30 regimen comprising Jasad Bhasma (classical Ayurveda Zinc preparation), Indukanth Kwatham tablets and powdered Curcuma amada (Amra-Haridra), was prescribed considering safety and efficacy in cancer treatment as discussed here. The Jasad bhasma (JB) is a bioabsorbable Rasayana preparation from Rasashashtra\textsuperscript{19}; the pharmacist treatise of Ayurveda. The safety and bioactivity studies of the JB are well studied and documented.\textsuperscript{20} It has the presence of macro-, micro-, and nano-particles\textsuperscript{21} in the final

\begin{table}
\centering
\small
\begin{tabular}{|c|c|c|}
\hline
\textbf{Event Chronology} & \textbf{Patient 1-PSK} & \textbf{Patient 2-BSK} \\
\hline
Age in years & 50 & 48 \\
Co-morbidity & Hypothyroidism 10 years & No \\
Family history & Not significant & Mother: ovarian cancer
Brother: non-Hodgkin lymphoma \\
Cancer antigen 125 (CA 125) at diagnosis & 158 U/mL & 2881 U/mL \\
Primary cytoreduction surgery & Total abdominal hysterectomy + bilateral salpingo-oophorectomy + omentectomy on 23/06/2010 & Total abdominal hysterectomy + bilateral salpingo-oophorectomy + omentectomy on 11/7/2015 \\
Diagnosis–histopathology report & Bilateral high-grade serous cyst-adenocarcinoma FIGO stage III-B & Bilateral grade III serous papillary adenocarcinoma FIGO stage III-B \\
\textbf{BRCA mutation} & Positive in intron 16 of the BRCAT gene C.5074+1G>A & Positive in exon 2 of the BRCA1 gene p.Glu23ValfsTer17 \\
\hline
\textbf{Previously received cancer therapies} & & \\
Chemotherapy 1st line & 6 cycles nanoparticle formulation of paclitaxel + carboplatin, last on 21/12/2010 & 6 cycles of paclitaxel + carboplatin last on 29/11/2015 \\
Recurrence 1 & 12/03/2013 (PFS: 26 months) & 25/07/2017 (PFS: 20 months) \\
Chemotherapy 2nd line & 6 cycles of gemcitabine + carboplatin, last on 23/09/2013 & 6 cycles of pegylated liposomal doxorubicin + carboplatin, last on 21/02/2018 \\
Recurrence 2 & 30/06/2016 (PFS: 33 months) & — \\
Chemotherapy 3rd line & 6 cycles of doxorubicin + carboplatin, last on 19/10/2016 & — \\
Recurrence 3 & 11/01/2018 (PFS: 15 months) & — \\
2nd cytoreduction surgery followed by chemotherapy 4th line & 6 cycles of liposomal doxorubicin + carboplatin until 02/07/2018 & — \\
\hline
\textbf{Ayurveda maintenance treatment ZINCA-30} & Progression-free survival (PFS) & \\
& Started from 02/07/2018 to 01/11/2020 & Started from 21/05/2018 till the date of latest follow up on 19/11/2021 \\
Present status & Recurrence 02/11/2020 (PFS: 28 months) & No recurrence until 19/11/2021 (PFS 45 months and continued) \\
\hline
\end{tabular}
\caption{Details of cancer treatment}
\end{table}
safe\textsuperscript{22} products manufactured as per the guidelines of Ayurvedic Formulary of India.\textsuperscript{23} JB is a zinc-based preparation, which was also studied in resistant ovarian cancer using SKOV3 and ES2 ovarian cancer cell lines and showed potential as a second-line treatment.\textsuperscript{24} \textit{Amra Haridra} (AH), as mentioned in Ayurvedic Pharmacopeia of India,\textsuperscript{25} commonly called as mango ginger and botanically known as \textit{Curcuma amada Roxb.} is a medicinal species of turmeric known for its anticancer potential, including ovarian cancer. It works by targeting the nuclear factor-\(\alpha\B) pathway in human ovarian cancer cell lines SKOV3ip1 and HeyA8.\textsuperscript{26,27} \textit{Indukant Kwatham} (IK)\textsuperscript{28–30} has therapeutic implications for the cases of intra-abdominal cysts, ovarian cysts, benign and malignant ovarian tumors termed as \textit{Raktaaja-Gulma}.\textsuperscript{31} \textit{Indukant Kwatham} has immunomodulatory effects after chemotherapy and is used in the form of aqueous or lipid extract.\textsuperscript{32,33} These patients were punctual for treatment and follow-up over the 3 years and continued to appear for their scheduled follow-ups. In these cases, the ZINCA-30 regimen was non-platinum based and the PFS observed was 28 months and 36.3 months. There were no reported or noted AEs during the entire period of treatment in these patients.

For the patients treated here, in whom the recurrence was observed after 28 months, the complete response (CR) was non-platinum based and the PFS observed was 28 months and 36.3 months. There were no reported or noted AEs during the entire period of treatment in these patients.

Therefore, the AMT ZINCA-30, being a non-platinum-based regimen may have a potential role in maintenance treatment after SOC as well as to increase the PFI, which eventually may lead to better OS, without any AEs or events.

Conclusion

1. Ayurveda maintenance therapy, ZINCA-30 can be a potential lead as an alternative non-platinum-based treatment option for increasing PFS in ROC.

2. The observations in these preliminary cases indicated increased PFI with AMT, ZINCA-30 after standard chemotherapy in ROC.

Limitations and Further Scope

This communication is merely a preliminary outcome of continued clinical observations, and a well-planned formal study is needed to test this hypothesis further.

Assessing the quality of life with the Global QOL Score and affordability can be studied in addition to this.

Conflict of Interest

None declared.

References:

31 Mishra BR, Katre SP. Raktaja Gulma in correlation with modern science conditions. Journal of Ayurveda and Integrated Medical Sciences 2018;3(02):73–77